Current Opinion in Urology最新文献

Urological impact of flozins (SGLT2 inhibitors): an EAU Endourology review of risks, side effects and clinical considerations. flozins （SGLT2抑制剂）对泌尿系统的影响：一项EAU泌尿系统的风险、副作用和临床考虑。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-24 DOI: 10.1097/MOU.0000000000001306

Ali Talyshinskii, Carlotta Nedbal, Bhaskar K Somani

{"title":"Urological impact of flozins (SGLT2 inhibitors): an EAU Endourology review of risks, side effects and clinical considerations.","authors":"Ali Talyshinskii, Carlotta Nedbal, Bhaskar K Somani","doi":"10.1097/MOU.0000000000001306","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001306","url":null,"abstract":"Purpose of review: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), also known as flozins, are one of the modern oral antidiabetic drugs. Currently, there are sufficient number of studies devoted to the effect of flozins on various genitourinary disorders, confirming their multifaceted positive and side effects. Thus, the purpose of this review is to analyze the current literature for an up-to-date definition of the role of these drugs in urological practice, prospects for their further study, and side effects that urologists need to remember when treating patients with T2DM taking flozins.Recent findings: Flozins (SGLT2i) are not linked to urological cancer risk, and might even lower the risk by disrupting tumor metabolism and cell cycle. Despite causing glucosuria, the resulting effect of Flozins is antilithogenic, which may be promising for patients with type 2 diabetes mellitus (T2DM) and kidney stone disease, especially regarding risk of recurrence. While the overall risk of UTI is not increased, flozins significantly increase the risk of genital mycotic infections. Flozins can worsen LUTS due to their diuretic action.Summary: Current results of studies on the use of flozins in patients with T2DM are promising for different spectrums of genitourinary diseases caused by different pathogenetic mechanisms. However, we need future clinical trials with specific drugs and comparisons to get trustworthy results about how helpful flozins are for these patients and whether they can be used in urology.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of suction devices in enhancing outcomes of retrograde intrarenal surgery: a narrative review by the YAU urolithiasis and section of EAU endourology. 吸引装置在提高逆行肾内手术结果中的作用：由YAU尿石症和EAU泌尿外科部分的叙述性回顾。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-21 DOI: 10.1097/MOU.0000000000001304

Mariela Corrales, Matthias Boeykens, Alba Sierra Del Rio, Eugenio Ventimiglia, Amelia Pietropaolo, Bhaskar Somani, Olivier Traxer

{"title":"The role of suction devices in enhancing outcomes of retrograde intrarenal surgery: a narrative review by the YAU urolithiasis and section of EAU endourology.","authors":"Mariela Corrales, Matthias Boeykens, Alba Sierra Del Rio, Eugenio Ventimiglia, Amelia Pietropaolo, Bhaskar Somani, Olivier Traxer","doi":"10.1097/MOU.0000000000001304","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001304","url":null,"abstract":"Purpose of review: To provide a comprehensive overview of existing literature on suction-assisted ureteroscopy, evaluating its effectiveness and associated complications.Recent findings: A literature review was conducted in December 2024 using the MEDLINE, EMBASE and Scopus databases by two independent authors. To structure and address the clinical question, \"Do suction devices improve outcomes in RIRS?\", we employed the PICOS (Patient, Intervention, Comparison, Outcome, Study Type) model. Exclusion criteria included case reports, studies involving suction techniques outside the context of endocorporeal laser lithotripsy (ELL), non-English language articles and articles or clinical trials with fewer than 15 patients.Summary: Among the 36 included studies, 28 studies focused on SUAS, of which seven specifically investigated SUAS with pressure measurement, three studies examined DISS, three studies evaluated SURE and two comparative studies analyzed different suction techniques. The presented results show that advancements in suction technology seem very promising and likely to shift endourological practice.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the impact of artificial intelligence-enabled decision aids in improving patient inclusivity, empowerment, and education in urology: a systematic review by EAU endourology. 探索人工智能辅助决策在提高泌尿外科患者包容性、赋权和教育方面的影响：EAU泌尿外科的系统综述。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-15 DOI: 10.1097/MOU.0000000000001301

Solomon Bracey, Nasif Bhuiyan, Amelia Pietropaolo, Bhaskar Somani

{"title":"Exploring the impact of artificial intelligence-enabled decision aids in improving patient inclusivity, empowerment, and education in urology: a systematic review by EAU endourology.","authors":"Solomon Bracey, Nasif Bhuiyan, Amelia Pietropaolo, Bhaskar Somani","doi":"10.1097/MOU.0000000000001301","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001301","url":null,"abstract":"Purpose of review: The implementation of artificial intelligence (AI) in urology has the potential to enhance patient outcomes through the provision of intelligent tools, such as AI-enabled decision aids (AIDAs), which can support personalized care. The objective of this systematic review is to determine the role of AIDAs in educating and empowering patients, particularly those from underrepresented populations.Recent findings: We conducted a comprehensive systematic review following PRISMA guidelines to explore the potential for AIDAs to address healthcare inequalities and promote patient education and empowerment. From 1078 abstracts screened, 21 articles were suitable for inclusion, all of which utilized chatbots. Three main themes of studies were identified. Fourteen studies focused on enhancing patient education, four studies investigated whether chatbots can improve the accessibility of urological literature and three studies explored chatbots role in providing lifestyle guidance. While chatbots demonstrated great potential as educational and lifestyle support tools, current research found mixed accuracy and a tendency for them to produce unreliable information. In terms of accessibility, chatbots were able to effectively enhance readability and translate literature, potentially bridging language, and literacy barriers.Summary: Through chatbots, AIDAs show strong potential to enhance urological education and empower underrepresented communities. However, chatbots must show greater consistency in accuracy before they can be confidently relied upon in clinical contexts. Further research evaluating chatbots' efficacy in clinical settings, especially with underrepresented groups, would enable greater understanding of their role in improving patient inclusivity, empowerment, and education.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prostate-specific antigen doubling time in prostate cancer: a review of calculation methods and clinical implications. 前列腺癌中前列腺特异性抗原加倍时间：计算方法和临床意义的综述。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-15 DOI: 10.1097/MOU.0000000000001303

Alfonso Romero Crespo, Daniel Carrasco Gomez, Nestor Manuel Sanchez Martinez, Carlos Bautista Vidal, Lydia Flores Sirvent, Rodrigo España Navarro, Emilio Garcia Galisteo

{"title":"Prostate-specific antigen doubling time in prostate cancer: a review of calculation methods and clinical implications.","authors":"Alfonso Romero Crespo, Daniel Carrasco Gomez, Nestor Manuel Sanchez Martinez, Carlos Bautista Vidal, Lydia Flores Sirvent, Rodrigo España Navarro, Emilio Garcia Galisteo","doi":"10.1097/MOU.0000000000001303","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001303","url":null,"abstract":"Purpose of review: Prostate-specific antigen doubling time (PSADT) is a key prognostic marker in prostate cancer, especially in cases of biochemical recurrence. It guides risk stratification and therapeutic decisions, but its calculation varies significantly across institutions. This review addresses the clinical relevance of PSADT and the need for standardized methods.Recent findings: Multiple models exist for PSADT calculation, including logarithmic regression, linear models, and nadir subtraction. Logarithmic regression best reflects PSA's exponential growth but requires at least three PSA values over time. Measurement variability - due to assay differences or sampling intervals - can affect PSADT estimates by 15-40%, impacting treatment decisions. Correction tools like the Memorial Sloan Kettering Cancer Center's Excel calculator have reduced variability by up to 30-40%, improving reliability.Summary: PSADT remains a valuable tool in prostate cancer management, particularly for guiding salvage therapies in biochemical recurrence. However, its accuracy depends on the calculation method and PSA measurement quality. Integrating validated tools like the MSKCC calculator and adopting standardized approaches can enhance clinical decision-making. This review underscores the need for improved harmonization of PSADT methodology across guidelines and clinical settings.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advancements in personalized management of prostate cancer biochemical recurrence after radical prostatectomy. 根治性前列腺切除术后前列腺癌生化复发的个体化治疗进展。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-15 DOI: 10.1097/MOU.0000000000001305

Fabian Falkenbach, Jonas Ekrutt, Tobias Maurer

{"title":"Recent advancements in personalized management of prostate cancer biochemical recurrence after radical prostatectomy.","authors":"Fabian Falkenbach, Jonas Ekrutt, Tobias Maurer","doi":"10.1097/MOU.0000000000001305","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001305","url":null,"abstract":"Purpose of review: Biochemical recurrence (BCR) after radical prostatectomy exhibits heterogeneous prognostic implications. Recent advancements in imaging and biomarkers have high potential for personalizing care.Recent findings: Prostate-specific membrane antigen imaging (PSMA)-PET/CT has revolutionized the BCR management in prostate cancer by detecting microscopic lesions earlier than conventional staging, leading to improved cancer control outcomes and changes in treatment plans in approximately two-thirds of cases. Salvage radiotherapy, often combined with androgen deprivation therapy, remains the standard treatment for high-risk BCR postprostatectomy, with PSMA-PET/CT guiding treatment adjustments, such as the radiation field, and improving progression-free survival. Advancements in biomarkers, genomic classifiers, and artificial intelligence-based models have enhanced risk stratification and personalized treatment planning, resulting in both treatment intensification and de-escalation.Summary: While conventional risk grouping relying on Gleason score and PSA level and kinetics remain the foundation for BCR management, PSMA-PET/CT, novel biomarkers, and artificial intelligence may enable more personalized treatment strategies.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicities of taxane-based chemotherapy in prostate cancer. 紫杉烷为基础的前列腺癌化疗的毒性。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-14 DOI: 10.1097/MOU.0000000000001296

Akihiro Matsukawa, Takafumi Yanagisawa, Paweł Rajwa, Takahiro Kimura

{"title":"Toxicities of taxane-based chemotherapy in prostate cancer.","authors":"Akihiro Matsukawa, Takafumi Yanagisawa, Paweł Rajwa, Takahiro Kimura","doi":"10.1097/MOU.0000000000001296","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001296","url":null,"abstract":"Purpose of review: Despite recent developments in the treatment of advanced prostate cancer (PCa), taxanes, including docetaxel (DOC) and cabazitaxel (CBZ), remain pivotal in management. DOC has shown efficacy for patients with metastatic hormone-sensitive prostate cancer, whereas CBZ plays a key role in the post-DOC setting. However, taxane-based therapies are associated with significant toxicities. We aimed to provide a comprehensive overview of the incidence, risk factors, and management strategies for taxane-related toxicities to optimize outcomes.Recent findings: Neutropenia and febrile neutropenia are life-threatening complications. Primary prophylactic granulocyte-colony stimulating factor (G-CSF) is recommended for CBZ. In contrast, evidence of its use with DOC is limited but should be considered for high-risk patients. Other common toxicities, such as nausea/vomiting, fatigue, neuropathy, and skin disorder, are generally nonlife-threatening but can significantly impair patients' quality of life (QoL). Tailored patient selection and individualized management strategies are essential for minimizing toxicities and ensuring treatment continuity.Summary: Despite the wide-ranging toxicities of taxanes, they remain a cornerstone in advanced PCa treatment. Preventing and managing severe neutropenia, febrile neutropenia, and QoL-impairing toxicities are essential for maintaining treatment continuity and achieving optimal outcomes.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicities of PARP inhibitors in genitourinary cancers. PARP抑制剂对泌尿生殖系统癌的毒性研究。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-07 DOI: 10.1097/MOU.0000000000001297

János Szalontai, Tibor Szarvas, Marcin Miszczyk, Péter Nyirády, Shahrokh F Shariat, Tamás Fazekas

{"title":"Toxicities of PARP inhibitors in genitourinary cancers.","authors":"János Szalontai, Tibor Szarvas, Marcin Miszczyk, Péter Nyirády, Shahrokh F Shariat, Tamás Fazekas","doi":"10.1097/MOU.0000000000001297","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001297","url":null,"abstract":"Purpose of review: Recent advancements in the understanding of the genetic background of genitourinary cancers allowed for a successful introduction of targeted antitumor agents to prostate cancer (PCa) treatment. Inhibitors of the poly ADP-ribose polymerase enzyme (PARPi) transformed the treatment landscape of metastatic prostate cancer, and being increasingly studied in earlier disease stages. However, they are associated with nonnegligible toxicity, therefore, we aimed to summarize their side-effect profile in patients with PCa.Recent findings: Hematologic toxicities, particularly anemia, thrombocytopenia, and neutropenia are among the most common and serious adverse events associated with PARPi, highlighting the need for regular blood count monitoring. Nonhematologic side effects, including fatigue, nausea, vomiting, diarrhea, and constipation, are common, and can be mitigated with supportive interventions like dietary modifications, antiemetics, or stool management techniques. Special attention should be given to patients with therapy-resistant or persistent cytopenia, in whom bone marrow biopsy should be considered, as it can indicate myelodysplastic syndrome and acute myeloid leukemia.Summary: PARP inhibitors represent a major advancement in the management of metastatic prostate cancer, offering a significant survival benefit in applicable cases. However, patients need to be carefully selected and informed, to allow for optimal balancing between the benefits and nonneglectable risks of severe toxicities. Better understanding of PARPi toxicity profile can improve personalized decision-making and enhance treatment compliance, through raising patients' awareness about the possible side effects of PARPi.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Obesity and BMI score as risk factors for urolithiasis: a systematic review over 30 years. 肥胖和BMI评分作为尿石症的危险因素：一项超过30年的系统回顾

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-06 DOI: 10.1097/MOU.0000000000001298

Megha Garg, Philip Joseph, Hans Johnson, Joseph Vayalil Lawrence, Bhaskar Somani, Bhavan Prasad Rai, Joe Philip

{"title":"Obesity and BMI score as risk factors for urolithiasis: a systematic review over 30 years.","authors":"Megha Garg, Philip Joseph, Hans Johnson, Joseph Vayalil Lawrence, Bhaskar Somani, Bhavan Prasad Rai, Joe Philip","doi":"10.1097/MOU.0000000000001298","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001298","url":null,"abstract":"Purpose of review: To examine association between high BMI, obesity, and kidney stone disease (KSD). For this, systematic review of empirical studies was performed using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA) guidelines. Cochrane Library, EMBASE, MEDLINE, CINAHL, AMED, Emcare, Clinicaltrials.gov, and WHO ICTRP were searched for English language population-based studies published from inception to October 2024, including adults aged at least 18 years reporting on high BMI, obesity and overweight, with incidence of KSD.Recent findings: The search identified 943 records, of which 15 relevant articles with 97 645 participants and 17 158 cases in total were enrolled in the narrative synthesis. A high heterogeneity and imbalance were observed among baseline distribution of cohorts in most studies. Thirteen studies provided comparative data on stone occurrence in obese and nonobese participants, and on per-patient analysis, three studies demonstrated a lower risk (RR < 1; 95% CI: 0.78-1.03), four studies a higher risk (RR>1; 95% CI: 0.77-2.32), and six studies depicted similar risk (RR = 1; 95% CI: 0.94-1.06) of stone occurrence between the two cohorts.Summary: Evidence in this study suggests an association between high BMI, being overweight, obesity, and increased risk of developing kidney stone disease. In the context of optimizing treatment, KSD should be considered a metabolic disease, with treatment to include dietary regimes, exercise intervention alongside pharmacotherapy to help reduce renal stone disease recurrence risk, alongside managing associated chronic diseases such as hypertension, type 2 diabetes mellitus, and coronary artery disease.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis. 放射配体和放射性同位素治疗前列腺癌的毒性：系统回顾和荟萃分析。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-06 DOI: 10.1097/MOU.0000000000001300

David Ventura, Benjamin Noto, Nadir Rodriguez Jauregui, Wolfgang Roll, Kambiz Rahbar

{"title":"Toxicities of radioligand and radioisotope therapy in prostate cancer: a systematic review and meta-analysis.","authors":"David Ventura, Benjamin Noto, Nadir Rodriguez Jauregui, Wolfgang Roll, Kambiz Rahbar","doi":"10.1097/MOU.0000000000001300","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001300","url":null,"abstract":"Purpose of review: This systematic review and meta-analysis investigate the toxicities of radioligand and radioisotope therapies - [177Lu]lutetium-prostate-specific membrane antigen (PSMA) (Lu-PSMA), [225Ac]actinium-PSMA (Ac-PSMA), and [223Ra]radium-dichloride (223-Radium) - in metastatic prostate cancer. While previous studies have explored this topic, most failed to differentiate between treatment-emergent adverse events (TEAEs) and preexisting conditions, leading to inflated toxicity rates. By focusing exclusively on TEAEs, this study provides a more accurate and clinically relevant assessment.Recent findings: This meta-analysis of 65 studies including 8706 patients identified haematotoxicities as the most frequent TEAEs across all therapies, affecting 10-20% of patients. Fatigue is a common nonhematologic adverse event in all treatments. Low grade xerostomia is specifically associated with Lu-PSMA and Ac-PSMA therapies, occurring in 30% and 84% of patients, respectively, while 223-Radium is uniquely linked to an increased fracture risk. Severe toxicities (Common Terminology Criteria for Adverse Events ≥ 3) are rare across all therapies. By clearly distinguishing TEAEs from baseline conditions, this study addresses a gap in the existing literature.Summary: Severe TEAEs are uncommon across Lu-PSMA, Ac-PSMA, and 223-Radium therapies. Still, monitoring and managing specific toxicities to optimize the safety and tolerability of these therapies in clinical practice is mandatory, especially concerning xerostomia in Ac-PSMA therapy.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing clinical risk stratification of localized prostate cancer. 优化局限性前列腺癌的临床风险分层。

IF 2.1 3区医学

Current Opinion in Urology Pub Date : 2025-05-02 DOI: 10.1097/MOU.0000000000001294

Vincent J Gnanapragasam

{"title":"Optimizing clinical risk stratification of localized prostate cancer.","authors":"Vincent J Gnanapragasam","doi":"10.1097/MOU.0000000000001294","DOIUrl":"https://doi.org/10.1097/MOU.0000000000001294","url":null,"abstract":"Purpose of review: To review the current risk and prognostic stratification systems in localised prostate cancer. To explore some of the most promising adjuncts to clinical models and what the evidence has shown regarding their value.Recent findings: There are many new biomarker-based models seeking to improve, optimise or replace clinical models. There are promising data on the value of MRI, radiomics, genomic classifiers and most recently artificial intelligence tools in refining stratification. Despite the extensive literature however, there remains uncertainty on where in pathways they can provide the most benefit and whether a biomarker is most useful for prognosis or predictive use. Comparisons studies have also often overlooked the fact that clinical models have themselves evolved and the context of the baseline used in biomarker studies that have shown superiority have to be considered.Summary: For new biomarkers to be included in stratification models, well designed prospective clinical trials are needed. Until then, there needs to be caution in interpretation of their use for day-to-day decision making. It is critical that users balance any purported incremental value against the performance of the latest clinical classification and multivariate models especially as the latter are cost free and widely available.","PeriodicalId":11093,"journal":{"name":"Current Opinion in Urology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0